STOCK TITAN

PolyPid receives $30M from Azurity in Q3 update

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

PolyPid Ltd. reported third-quarter 2026 results and a corporate update, including $30 million received from Azurity. D-PLEX₁₀₀ is under FDA priority review, with a PDUFA goal date of November 28, 2026; Azurity is preparing for a potential U.S. commercial launch, subject to approval. PolyPid said its MAA for D-PLEX₁₀₀ was submitted and validated by the EMA and that it regained European commercialization rights.

The company introduced PD01B, a Kynatrix-based product candidate for diabetic foot infections, under its PolyPid 2030 strategy. Net loss was $5.754 million for the three months ended September 30, 2026, versus $7.451 million for the three months ended September 30, 2025; nine-month net loss was $21.331 million versus $25.696 million for the corresponding 2025 period. Operating loss was $5.922 million for the three months ended September 30, 2026, versus $7.455 million for the same period in 2025; nine-month operating loss was $21.531 million versus $24.437 million.

At September 30, 2026, cash and cash equivalents were $5.414 million and short-term deposits were $10.085 million. Deferred revenues were $30 million, compared with $2.548 million at December 31, 2025.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Moderate pointQuarterly net loss narrowed to $5.754 million from $7.451 million.

Negative

  • None.

Filing Explained

At September 30, 2026, the higher share count meant an unchanged holding represented a smaller fraction of PolyPid than at December 31, 2025.

PolyPid’s Form 6-K furnishes its November 11 corporate update and third-quarter results. The balance sheet lists 21,125,704 ordinary shares issued and outstanding at September 30, 2026, versus 18,204,002 at December 31, 2025; for an unchanged holding, the higher total means a smaller ownership fraction.

The filing incorporates specified sections of the release into the company’s listed Form F-3 and Form S-8 registration statements from submission, unless later superseded, making those sections part of those filings.

Amount received from Azurity $30 million Corporate update
PDUFA goal date November 28, 2026 D-PLEX₁₀₀ is under FDA priority review
Net loss $5.754 million Three months ended September 30, 2026
Net loss $7.451 million Three months ended September 30, 2025
Net loss $21.331 million Nine months ended September 30, 2026
Net loss $25.696 million Nine months ended September 30, 2025
Cash and cash equivalents $5.414 million At September 30, 2026
Short-term deposits $10.085 million At September 30, 2026
PDUFA goal date regulatory
"PDUFA goal date of November 28, 2026"
The PDUFA goal date is the target deadline set by the U.S. Food and Drug Administration for completing its review of a new drug or biologic application. Investors watch it like a court date for a product: the outcome (approval, rejection, or request for more information) can sharply change a company’s revenue prospects and stock price, and the date gives a predictable event around which markets and planning can focus.
MAA regulatory
"the MAA for D-PLEX₁₀₀"
MAA stands for Marketing Authorization Application, the formal request a drug developer files with regulators (commonly in the European Union) asking for permission to sell a medicine. Think of it like applying for a driver’s license for a product: approval means the company can market and earn revenue from the drug, while rejection or delays affect expected sales, timelines and the company’s valuation—so investors track MAAs as key risk/reward milestones.
Kynatrix technology technical
"advance Kynatrix technology through additional pipeline programs"
NTAP regulatory
"anticipated timing of a CMS decision on NTAP"
NTAP is a stock exchange ticker symbol — a short code used to identify a particular company’s publicly traded shares on an exchange. For investors it matters because the ticker is the quick identifier used to look up real-time prices, trade the stock, check ownership and find news or filings; think of it like a vehicle’s license plate that instantly points you to everything specific about that car in traffic.
deferred revenues financial
"Deferred revenues"
Deferred revenues are cash a company has received up front for goods or services it has not yet delivered; the company records this as a promise to fulfill an obligation later rather than as current earned sales. Investors care because deferred revenues show how much future work a firm must complete before that cash counts as profit, similar to buying a prepaid subscription or gift card that the seller still needs to honor.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did PYPD receive from Azurity?

PolyPid reported receiving $30 million from Azurity.

What was PYPD's third-quarter 2026 net loss?

PolyPid reported a net loss of $5.754 million for the three months ended September 30, 2026, compared with $7.451 million for the three months ended September 30, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of: November 2026

 

Commission File Number: 001-38428

 

PolyPid Ltd.

(Translation of registrant’s name into English)

 

18 Hasivim Street

Petach Tikva 495376, Israel

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

☒ Form 20-F      ☐ Form 40-F

 

 

 

 

 

CONTENTS

 

Attached hereto and incorporated herein is PolyPid Ltd.’s (the “Registrant”) press release issued on November 11, 2026, titled “PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results.”

 

The first paragraph and the sections titled “Recent Corporate Highlights”, “Financial Results for the Three Months Ended September 30, 2026”, “Financial Results for the Nine Months Ended September 30, 2026”, “Balance Sheet Highlights”, and “Forward-looking Statements” in the press release attached hereto as Exhibit 99.1 are incorporated by reference into the Registrant’s registration statements on Form F-3 (File No. 333-276826, File No. 333-280658, File No. 333-281863, File No. 333-284376 and File No. 333-289034)  and Form S-8 (File No. 333-239517, File No. 333-271060, File No. 333-277703, File No. 333-280662, File No. 333-289570 and File No. 333-298261) filed  with the Securities and Exchange Commission to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 

 

1

 

EXHIBIT INDEX

 

Exhibit No.    
99.1   Press Release issued by PolyPid Ltd. on November 11, 2026, titled “PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results.”

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  POLYPID LTD.
     
Date: November 12, 2026 By: /s/ Dikla Czaczkes Akselbrad
    Name: Dikla Czaczkes Akselbrad
    Title: Chief Executive Officer

 

3

 

Exhibit 99.1 

 

 

 

PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results

 

D-PLEX₁₀₀ NDA Under FDA Priority Review with PDUFA Goal Date of November 28, 2026; U.S.
Commercial Launch Preparations Ongoing

 

Expanding D-PLEX₁₀₀ Globally: MAA Submitted and Validated by the EMA and European
Commercialization Rights to D-PLEX₁₀₀ Regained

 

“PolyPid 2030” Growth Strategy Unveiled, Introducing PD01B, a New Kynatrix™-Based Product
Candidate for the Treatment of Diabetic Foot Infections

 

$30 Million Received from Azurity

 

Conference Call Scheduled for Today at 8:30 AM ET

 

PETACH TIKVA, Israel, November 11, 2026 - PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today provided a corporate update and reported financial results for the three and nine months ended September 30, 2026.

 

Recent Corporate Highlights:

 

D-PLEX₁₀₀ Under U.S. Food and Drug Administration (“FDA”) Priority Review; PolyPid and Azurity Preparing for Potential U.S. Launch:

 

●The FDA is reviewing the New Drug Application (“NDA”) for D-PLEX₁₀₀ for the prevention of surgical site infections (“SSIs”) in patients undergoing colorectal surgery under Priority Review, with a Prescription Drug User Fee Act (“PDUFA”) goal date of November 28, 2026. Labeling discussions with the FDA are underway, and all scheduled FDA interactions are on track and aligned with the PDUFA goal date.

 

●Subject to approval, PolyPid and Azurity Pharmaceuticals (“Azurity”) are preparing for the U.S. commercial launch of D-PLEX₁₀₀ in early 2027. Azurity is building its U.S. commercial organization, with an existing hospital footprint that reaches more than 1,700 leading U.S. hospitals and academic centers.

 

●A New Technology Add-on Payment (“NTAP”) application for D-PLEX₁₀₀ has been submitted to the Centers for Medicare & Medicaid Services (“CMS”), with a decision expected in August 2027. If granted, NTAP would provide additional hospital reimbursement for D-PLEX₁₀₀ in the inpatient setting.

 

●PolyPid has received a total of $30 million in upfront and near-term milestone payments from Azurity, comprising $15 million upon signing of the agreement in July 2026 and an additional $15 million milestone payment following FDA acceptance of the NDA, received subsequent to September 30, 2026. PolyPid remains eligible for over $290 million in additional regulatory, launch and sales-based milestone payments. In addition, upon commercialization, PolyPid will receive a pre-negotiated transfer price for each unit of D-PLEX₁₀₀ it manufactures and supplies to Azurity, as well as tiered royalties ranging from mid-teen to mid-twenties percentages on sales in the U.S. and Canada.

 

 

 

Expanding D-PLEX₁₀₀ Globally:

 

●On September 14, 2026, PolyPid submitted its Marketing Authorization Application (“MAA”) for D-PLEX₁₀₀ to the European Medicines Agency (“EMA”) under the Centralized Procedure, meeting its previously communicated third quarter 2026 timeline. Subsequent to quarter end, the EMA validated the MAA, initiating its formal review. A decision is expected in the second half of 2027.

 

●PolyPid and ADVANZ PHARMA mutually agreed to terminate their 2022 exclusive License, Distribution and Supply Agreement for D-PLEX₁₀₀ in Europe, and exclusive European commercialization rights to D-PLEX₁₀₀ have reverted to PolyPid.

 

●The Company is in active discussions with potential commercial partners in Europe.

 

“PolyPid 2030” Strategy and Expanded Kynatrix™ Pipeline:

 

●Subsequent to quarter end, on October 28, 2026, PolyPid hosted its “PolyPid 2030” virtual investor day and KOL event, outlining a long-term growth strategy built on three levers: maximizing D-PLEX₁₀₀ through the Azurity partnership, including label expansion beyond colorectal surgery; expanding D-PLEX₁₀₀ into Europe and other territories through partnerships; and building a Kynatrix-based pipeline.

 

●Introduced PD01B, a new hyper-localized Kynatrix-based product candidate for the treatment of moderate to severe diabetic foot infections following wound debridement. PD01B is designed to deliver high-concentration doxycycline in the wound for weeks and is expected to be developed under its own NDA, separate from D-PLEX₁₀₀. PD01B leverages the active ingredient, Kynatrix technology, manufacturing site and processes, and preclinical and safety foundation established for D-PLEX₁₀₀. PolyPid holds worldwide commercial rights to PD01B.

 

●PolyPid’s long-acting obesity program, PD03A, continues in early preclinical development.

 

“With our PDUFA goal date fast approaching, this is a defining moment for PolyPid,” said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. “We have a committed partner in Azurity preparing to bring D-PLEX₁₀₀ to surgeons and patients in the U.S., subject to approval, and we now hold full rights to D-PLEX₁₀₀ in Europe. As D-PLEX₁₀₀ moves toward commercialization, we are leveraging the Kynatrix technology to strengthen our pipeline. At our recent investor day, we presented how it can reach beyond surgical site infections, starting with PD01B in diabetic foot infections, a serious condition where systemic antibiotics often fall short. We are now focused on executing our PolyPid 2030 plan, and we look forward to sharing our progress.”

 

Upcoming Expected Milestones:

 

●PDUFA goal date for the D-PLEX₁₀₀ NDA of November 28, 2026.

 

●Initiation of FDA communications on label expansion of D-PLEX₁₀₀ into broader abdominal surgery in the fourth quarter of 2026.

 

●Potential U.S. commercial launch of D-PLEX₁₀₀ by Azurity in early 2027.

 

●New Drug Submission for D-PLEX₁₀₀ in Canada in 2027.

 

●CMS decision on NTAP for D-PLEX₁₀₀ in August 2027.

 

●EMA decision on the D-PLEX₁₀₀ MAA in the second half of 2027.

 

●PD01B pre-Investigational New Drug (“IND”) meeting with the FDA and first-in-human study, both expected in the second half of 2027.

 

2

 

Financial Results for the Three Months Ended September 30, 2026

 

●Research and development expenses for the three months ended September 30, 2026, were $6.5 million, compared to $5.3 million in the same three-month period of 2025. The increase was primarily due to the ongoing NDA-related activities and continued commercial readiness preparation.

 

●General and administrative expenses for the three months ended September 30, 2026, were $1.5 million, compared to $1.8 million for the same period of 2025. The decrease was primarily due to the decrease of non-cash expenses related to performance-based options following the positive Phase 3 SHIELD II topline results, which triggered the vesting of those options.

 

●Marketing and business development expenses for the three months ended September 30, 2026, were $0.4 million, compared to $0.4 million for the same period of 2025.

 

●Other income for the three months ended September 30, 2026, was $2.5 million, reflecting the recognition of previously deferred revenue following the termination of the ADVANZ agreement on September 30, 2026.

 

●For the three months ended September 30, 2026, the Company had a net loss of $5.8 million, or $(0.24) per share, compared to a net loss of $7.5 million, or $(0.37) per share, in the three-month period ended September 30, 2025.

 

Financial Results for the Nine Months Ended September 30, 2026

 

●Research and development expenses for the nine months ended September 30, 2026, were $18.4 million, compared to $17.6 million in the same nine-month period of 2025. The increase was primarily due to the ongoing NDA-related activities and continued commercial readiness preparation.

 

●General and administrative expenses for the nine months ended September 30, 2026, were $4.4 million, compared to $5.4 million for the same period of 2025. The decrease was primarily due to the decrease of non-cash performance-based options vesting expenses.

 

●Marketing and business development expenses for the nine months ended September 30, 2026, were $1.3 million, compared to $1.4 million for the same period of 2025.

 

●Other income for the nine months ended September 30, 2026, was $2.5 million, as described above.

 

●For the nine months ended September 30, 2026, the Company had a net loss of $21.3 million, or $(0.94) per share, compared to a net loss of $25.7 million, or $(1.72) per share, in the nine-month period ended September 30, 2025.

 

3

 

Balance Sheet Highlights

 

●As of September 30, 2026, the Company had cash, cash equivalents and short-term deposits of $15.5 million, compared to $12.9 million on December 31, 2025. Following the end of the quarter, the Company received an additional $15 million milestone payment from its U.S. partner, Azurity, following the FDA’s acceptance of the D-PLEX₁₀₀ NDA, further strengthening its balance sheet.

 

●The Company believes that its current cash position, together with its expected proceeds from its commercialization agreement with Azurity, as well as future potential proceeds, will be sufficient to fund operations into 2028 and through several significant upcoming potential milestones.

 

Conference Call Dial-In & Webcast Information:

 

Date: Wednesday, November 11, 2026
Time: 8:30 AM Eastern Time
Conference Call: https://register-conf.media-server.com/register/BIa693ec3496b1413b8682b952b2ff9e10
Webcast: https://edge.media-server.com/mmc/p/rsj3o3mw

 

About PolyPid

 

PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid’s lead product, D-PLEX₁₀₀, successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections. Guided by a commitment to precision and innovation, PolyPid is redefining how therapies perform and raise the standard of patient care. For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.

 

4

 

Forward-looking Statements

 

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the FDA’s review of the D-PLEX₁₀₀ NDA, including the PDUFA goal date, the outcome and timing of such review, the Company’s ongoing labeling discussions with the FDA, and the potential approval of D-PLEX₁₀₀; the anticipated timing of a potential U.S. commercial launch of D-PLEX₁₀₀ by Azurity and Azurity’s launch preparations; potential reimbursement for D-PLEX₁₀₀, including the anticipated timing of a CMS decision on NTAP; the timing, receipt and amount of regulatory, launch and sales-based milestone payments, transfer price payments and royalties under the Company’s agreement with Azurity; the potential label expansion of D-PLEX₁₀₀, including the planned initiation of communications with the FDA and the anticipated timing of potential label expansion; the EMA’s review of the MAA for D-PLEX₁₀₀, the anticipated timing of a decision and a potential EU launch; the Company’s plans for the commercialization of D-PLEX₁₀₀ in Europe and other territories, including potential partnerships; the planned New Drug Submission for D-PLEX₁₀₀ in Canada; the Company’s “PolyPid 2030” growth strategy; the design, development plan, regulatory pathway and anticipated timing of a pre-IND meeting and first-in-human study for PD01B, and its potential benefits; the Company’s plans to advance Kynatrix technology through additional pipeline programs, including its long-acting obesity program, PD03A, and the anticipated development and potential applications of such programs; the Company’s belief that its current cash position, together with its expected proceeds from its commercialization agreement with Azurity, as well as future potential proceeds, will be sufficient to fund operations into 2028 and through several significant upcoming potential milestones; and the therapeutic and commercial potential of D-PLEX₁₀₀. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission, including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed on February 25, 2026. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

 

Company Contact:

 

PolyPid Ltd.
Ori Warshavsky
908-858-5995
IR@Polypid.com

 

Investor Relations Contact:

 

Arx Investor Relations
North American Equities Desk
polypid@arxhq.com

 

5

 

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

U.S. dollars in thousands

 

   September 30,   December 31, 
   2026   2025 
         
ASSETS        
         
CURRENT ASSETS:        
Cash and cash equivalents  $5,414   $6,402 
Restricted deposits   201    193 
Short-term deposits   10,085    6,531 
Accounts receivable   15,000    - 
Pre-launch inventories   1,567    1,106 
Prepaid expenses and other current assets   901    995 
           
Total current assets   33,168    15,227 
           
NON-CURRENT ASSETS:          
Property and equipment, net   4,553    5,094 
Operating lease right-of-use assets   1,181    1,675 
Long-term deposits   318    311 
Other long-term asset   900    - 
           
Total non-current assets   6,952    7,080 
           
Total assets  $40,120   $22,307 

 

6

 

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

U.S. dollars in thousands (except share and per share data)

 

   September 30,   December 31, 
   2026   2025 
         
LIABILITIES AND SHAREHOLDERS’ EQUITY        
         
CURRENT LIABILITIES:        
Trade payables  $1,573   $2,856 
Accrued expenses and other current liabilities   2,981    2,734 
Current maturities of long-term debt   -    988 
Current maturities of operating lease liabilities   1,030    1,161 
           
Total current liabilities   5,584    7,739 
           
NON-CURRENT LIABILITIES:          
Deferred revenues   30,000    2,548 
Long-term operating lease liabilities   227    647 
Long-term other liabilities   408    400 
           
Total non-current liabilities   30,635    3,595 
           
COMMITMENTS AND CONTINGENT LIABILITIES           
           
SHAREHOLDERS’ EQUITY:          
Ordinary shares, no par value -          
Authorized: 107,800,000 shares at September 30, 2026 and December 31, 2025; Issued and outstanding: 21,125,704 and 18,204,002 shares at September 30, 2026 and December 31, 2025, respectively   -    - 
Additional paid-in capital   326,732    312,473 
Accumulated deficit   (322,831)   (301,500)
           
Total shareholders’ equity   3,901    10,973 
           
Total liabilities and shareholders’ equity  $40,120   $22,307 

 

7

 

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

U.S. dollars in thousands (except share and per share data)

 

   Nine Months Ended   Three Months Ended 
   September 30,   September 30, 
   2026   2025   2026   2025 
                 
                 
Operating expenses:                
Research and development  $18,404   $17,589   $6,523   $5,257 
Marketing and business development   1,291    1,421    418    432 
General and administrative   4,384    5,427    1,529    1,766 
Other income   (2,548)   -    (2,548)   - 
                     
Operating loss   21,531    24,437    5,922    7,455 
Loss on extinguishment of debt   -    512    -    - 
Financial expense (income), net   (208)   661    (170)   (26)
                     
Loss before income tax   21,323    25,610    5,752    7,429 
Income tax expenses   8    86    2    22 
                     
Net loss  $21,331   $25,696   $5,754   $7,451 
                     
Basic and diluted loss per ordinary share  $0.94   $1.72   $0.24   $0.37 
                     
Weighted average number of ordinary shares used in computing basic and diluted loss per share   22,751,434    14,920,521    23,677,711    20,054,071 

 

 

8

 

Filing Exhibits & Attachments

1 document

Keep reading